Drug Monograph

Drug/Drug Class:	**Dupixent® (dupilumab) syringe for injection / Interleukin-4 receptor antagonists**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Dupixent® is now available in a single-dose pre-filled syringe containing 200 mg dupilumab per 1.14 mL solution.
Manufacturer:	Regeneron Pharmaceuticals, Inc. Tarrytown, NY 10591
Indications:	Dupixent® is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent® can be used with or without topical corticosteroids. Also, as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Costs:	$1,459.90 per 200 mg syringe of Dupixent®. Maximum Allowable Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Under Solicitation ☐ Appropriate Indications ☐ No PA Required

Prepared By: Jennifer Anderson PharmD
Date: November 26, 2018